Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in transfusion-dependent thalassemia intermedia after inadequate hydroxyurea response
IRCT20180603039959N5Phase 2Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in beta-thalassemia intermedia, sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: Change in hemoglobin levels before and after the intervention, Blood transfusion requirement before and after the intervention and 1 more. Started Feb 2025; status: completed.
02
Drugs
thalidomide
03
Conditions
beta-thalassemia intermedia
Beyond the preview
Go deeper on IRCT20180603039959N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180603039959N5.